Two-year experience with balloon-expandable transcatheter aortic valve replacement in severe aortic stenosis at a tertiary center


Şahin A., Canpolat A. C., Gül E., Çerik İ. B., Gül İ.

Cumhuriyet Tıp Dergisi (ELEKTRONİK), cilt.46, sa.2, ss.129-135, 2024 (Hakemli Dergi)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 46 Sayı: 2
  • Basım Tarihi: 2024
  • Doi Numarası: 10.7197/cmj.1474981
  • Dergi Adı: Cumhuriyet Tıp Dergisi (ELEKTRONİK)
  • Derginin Tarandığı İndeksler: Index Copernicus
  • Sayfa Sayıları: ss.129-135
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Objective Aortic stenosis (AS) is the most common valvular heart disease requiring intervention, particularly in developed countries. Transcatheter aortic valve replacement (TAVR) is indicated for patients with a high surgical risk and a post-procedural survival expectancy of more than 12 months. Over the years, the TAVR method has emerged as a significant treatment option for patients with symptomatic severe AS and has begun to be implemented in our country as well. The objective of this study was to evaluate the short and long-term outcomes of patients undergoing TAVR at our center, as well as to assess our institution's experience with the TAVR procedure. Methods This retrospective, single-center analysis included 16 consecutive patients with symptomatic AS who underwent TAVR between March 2022 and February 2024. All patients included in the study underwent implantation of a balloon-expandable TAVR valve. In the study, the demographic characteristics of patients preoperatively and during post-procedural follow-ups, their clinical status preoperatively and postoperatively, and echocardiographic findings were evaluated and compared. Results The mean age of the entire population was 78.3 ± 8.7 years, and 50% were women. Transfemoral access was used in 93.8% of patients. Implantation success was achieved in all cases. During the TAVI procedure, 12.5% of patients required permanent pacemaker implantation. The mean length of hospital stay for the entire cohort was 4.5±2.3 days. There wasn’t show in-hospital deaths occurred before hospital discharge. During the follow-up, it was observed that 3 patients died from all-cause mortality. The mean follow-up duration of the study was 552 days, with the longest follow-up being 666 days. The significant improvement was noted in all echocardiographic parameters and functional capacity. No cases with moderate or severe aortic regurgitation, necessitating additional procedures. Conclusion Our center results with TAVR over a 2-year span consistent with broader studies. Despite some procedure-related complications, advancements in devices and techniques are expected to reduce these, enhancing outcomes with increased procedural experience. With medicine favoring less invasive approaches, TAVR is poised to become a more prevalent alternative to surgery across diverse patient cohorts.